Protocol summary
-
Study aim
-
Objective: The aim of this study is to determine the effects of melatonin supplementation on hormonal profiles, inflammatory factors, oxidative stress biomarkers and gene expression related to inflammation in patients with polycystic ovary syndrome.
-
Design
-
Study design: Randomized double-blind placebo-controlled trial. Randomization will be done by the use of computer-generated random numbers. Patients will be assigned into two groups to receive supplements (n=30) or placebo (n=30).
-
Settings and conduct
-
Among patients with polycystic ovary syndrome referred to Kosar outpatient Clinic affiliated to Arak University of Medical Sciences, 60 patients will be selected according to inclusion and exclusion criteria. Participants, investigators or the assessors of the outcomes are unaware of the study groups. Supplements and placebos are similar in shape and size. Fasting blood samples will be taken at baseline and 12 weeks after the intervention. At the beginning and the end of the intervention: 12 weeks.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients with polycystic ovary syndrome aged 18 to 40 years. Exclusion criteria: Pregnancy, breastfeeding, patients with sleeping disorders, adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, thyroid dysfunction and/or diabetes.
-
Intervention groups
-
Intervention group: 10 mg melatonin (Zahravi Pharmaceutical Company,Tabriz, Iran) daily for 12 weeks orally. Control group: Placebo (Barij Essence, Kashan, Iran), daily for 12 weeks orally.
-
Main outcome variables
-
Outcomes: Malondialdehyde (primary outcome) and hormonal profiles, inflammatory factors and gene expression related to inflammation (secondary outcome) will be quantified at study baseline and end-of-trial.
General information
-
Reason for update
-
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT2017082733941N9
Registration date:
2017-09-18, 1396/06/27
Registration timing:
retrospective
Last update:
2019-09-16, 1398/06/25
Update count:
1
-
Registration date
-
2017-09-18, 1396/06/27
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Expected recruitment start date
-
2017-08-15, 1396/05/24
-
Expected recruitment end date
-
2017-08-30, 1396/06/08
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Clinical trial of the effect of melatonin supplementation compared with the placebo on hormonal profiles, inflammatory factors, oxidative stress biomarkers and gene expression related to inflammation in women with polycystic ovary syndrome
-
Public title
-
Effect of melatonin supplementation in treatment of women with polycystic ovary syndrome
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Patients with polycystic ovary syndrome aged 18 to 40 years
Exclusion criteria:
Pregnancy
Breastfeeding
Patients with sleeping disorders
Adrenal hyperplasia
Androgen-secreting tumors
Hyperprolactinemia
Thyroid dysfunction and/or diabetes
-
Age
-
From 18 years old to 40 years old
-
Gender
-
Female
-
Phase
-
N/A
-
Groups that have been masked
-
- Participant
- Investigator
- Outcome assessor
-
Sample size
-
Target sample size:
60
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
To decrease potential confounding effects, after balanced randomisation, participants will be allocated into two treatment groups to take either supplements or placebo. Randomization will be done by the use of computer software.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Participants, investigators or the assessors of the outcomes are unaware of the study groups.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2017-08-14, 1396/05/23
-
Ethics committee reference number
-
IR.ARAKMU.REC.1396.89
Health conditions studied
1
-
Description of health condition studied
-
Polycystic ovary syndrome
-
ICD-10 code
-
E28.2
-
ICD-10 code description
-
Polycystic ovarian syndrome
Primary outcomes
1
-
Description
-
Malondialdehyde
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Spectrophotometry
Secondary outcomes
1
-
Description
-
Glutathione
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Spectrophotometry
2
-
Description
-
Total antioxidant capacity
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Spectrophotometry
3
-
Description
-
Total testosterone
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
4
-
Description
-
SHBG
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
5
-
Description
-
Hs-CRP
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Elisa kit
6
-
Description
-
Nitric oxide
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Spectrophotometry
7
-
Description
-
Expressed levels of TNF-a gene
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
PCR
8
-
Description
-
Expressed levels of IL-1 gene
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
PCR
9
-
Description
-
Expressed levels of IL-8 gene
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
PCR
10
-
Description
-
Expressed levels of TGFB gene
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
PCR
11
-
Description
-
Expressed levels of VEGF gene
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
PCR
12
-
Description
-
Modified Ferriman Gallwey
-
Timepoint
-
At the beginning of the study and after 12 weeks of intervention
-
Method of measurement
-
Questioner
Intervention groups
1
-
Description
-
Intervention group: Melatonin supplements (Zahravi, Tabriz, Iran), 5 mg, two capsules one hour before bedtime for 12 weeks orally.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Placebo capsule (Barij Essence, Kashan, Iran), two capsules one hour before bedtime for 12 weeks orally.
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Vice chancellor for research, Arak University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available